갑상선 유두암과 신체질량지수 간의 임상병리학적 관련성
Clinicopathological Relevance between Body Mass Index and Papillary Thyroid Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Obesity is a known risk factor for several cancers, including breast, colon, esophagus, kidney, uterus, and thyroid. Recent studies have reported that higher body mass index (BMI) is also associated with more advanced stage. The aim of this study was to investigate the clinicopathological relevance between BMI and papillary thyroid carcinoma (PTC). Methods: A total of 798 patients surgically treated for PTC from January 2006 to June 2010 were included in this study. Medical records and pathologic reports were reviewed retrospectively. According to BMI, patients were divided into four groups: underweight (3.1%), normal (57.3%), overweight (31.6%), and obese (8.0%). Clinicopathological factors were analyzed and compared between normal and other groups. Results: According to the results, 709 patients were women (89.0%) and mean age was 48.5 years; mean follow-up period was 1,721±464.2 days. In comparison between the normal and underweight groups, there was significantly more extra-thyroidal invasion [Odds ratio (OR) 3.923, P=0.006] in the underweight group. In the obese group, tumor size was significantly larger (OR 1.794, P=0.007). However, there was no significant difference between the normal and overweight group. Conclusion: In the obese group, tumor size was the only clinical significant factor between high BMI and PTC. Interestingly, more extra-thyroidal invasion was seen in the underweight group. To confirm this result, further studies with long-term follow-up and more patients are required.
Abstract
Purpose: Obesity is a known risk factor for several cancers, including breast, colon, esophagus, kidney, uterus, and thyroid. Recent studies have reported that higher body mass index (BMI) is also associated with more advanced stage. The aim of this study was to investigate the clinicopathological relevance between BMI and papillary thyroid carcinoma (PTC). Methods: A total of 798 patients surgically treated for PTC from January 2006 to June 2010 were included in this study. Medical records and pathologic reports were reviewed retrospectively. According to BMI, patients were divided into four groups: underweight (3.1%), normal (57.3%), overweight (31.6%), and obese (8.0%). Clinicopathological factors were analyzed and compared between normal and other groups. Results: According to the results, 709 patients were women (89.0%) and mean age was 48.5 years; mean follow-up period was 1,721±464.2 days. In comparison between the normal and underweight groups, there was significantly more extra-thyroidal invasion [Odds ratio (OR) 3.923, P=0.006] in the underweight group. In the obese group, tumor size was significantly larger (OR 1.794, P=0.007). However, there was no significant difference between the normal and overweight group. Conclusion: In the obese group, tumor size was the only clinical significant factor between high BMI and PTC. Interestingly, more extra-thyroidal invasion was seen in the underweight group. To confirm this result, further studies with long-term follow-up and more patients are required.
참고문헌 (30)
- Pellegriti G, "Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors", J Cancer Epidemiol, 2013, pp.965212~ (2013)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010", Cancer Research and Treatment, 45(1), pp.1~14 (2013), 대한암학회[DOI]
- Chen AY, "Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005", Cancer, 115, pp.3801~3807 (2009)
- Pazaitou-Panayiotou K, "Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms", Obes Rev, 14, pp.1006~1022 (2013)
- Misra A, "Obesity and the metabolic syndrome in developing countries", J Clin Endocrinol Metab, 93(11 Suppl 1), pp.S9~S30 (2008)
- Lim S, "Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007", Diabetes Care, 34, pp.1323~1328 (2011)
- De Pergola G, "Obesity as a major risk factor for cancer", J Obes, 2013, pp.291546~ (2013)
- Su LJ, "Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study", Cancer Epidemiol Biomarkers Prev, 20, pp.844~853 (2011)
- Kaviani A, "Effects of obesity on presentation of breast cancer, lymph node metastasis and patient survival: a retrospective review", Asian Pac J Cancer Prev, 14, pp.2225~2229 (2013)
- Harari A, "Risk of advanced papillary thyroid cancer in obese patients", Arch Surg, 147, pp.805~811 (2012)
- Ju-Yeon Kim, "The indices of body size and aggressiveness of papillary thyroid carcinoma", 대한외과학회지, 80(4), pp.241~244 (2011), 대한외과학회
- Kim HJ, "Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer", Clin Endocrinol, 78, pp.134~140 (2013)
- Paes JE, "The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study", J Clin Endocrinol Metab, 95, pp.4244~4250 (2010)
- Obesity:preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, "World Health Organization Consultation on Obesity", World Health Organization, 1~276 (1997)
- Edge SB, "AJCC cancer staging manual" (2010), Springer
- Navarro Silvera SA, "Risk factors for thyroid cancer: a prospective cohort study", Int J Cancer, 116, pp.433~438 (2005)
- Álvarez-Castro P, "Endocrine function in obesity", Endocrinol Nutr, 58, pp.422~432 (2011)
- Nguyen NT, "Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004", J Am Coll Surg, 207, pp.928~934 (2008)
- Vucenik I, "Obesity and cancer risk: evidence, mechanisms, and recommendations", Ann N Y Acad Sci, 1271, pp.37~43 (2012)
- Oh SW, "Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study", J Clin Oncol, 23, pp.4742~4754 (2005)
- Renehan AG, "Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies", Lancet, 371, pp.569~578 (2008)
- Kitahara CM, "Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies", Cancer Epidemiol Biomarkers Prev, 20, pp.464~472 (2011)
- Brindel P, "Anthropometric factors in differentiated thyroid cancer in French Polynesia: a case-control study", Cancer Causes Control, 20, pp.581~590 (2009)
- Ramos-Nino ME, "The role of chronic inflammation in obesity-associated cancers", ISRN Oncol, 2013, pp.697521~ (2013)
- Liotti F, "Inflammation in thyroid oncogenesis", Am J Cancer Res, 2, pp.286~297 (2012)
- Shih SR, "Diabetes and thyroid cancer risk: literature review", Exp Diabetes Res, 2012, pp.578285~ (2012)
- Hedayati M, "Leptin: a correlated Peptide to papillary thyroid carcinoma?", J Thyroid Res, 2011, pp.832163~ (2011)
- Bouloumié A, "Leptin, the product of Ob gene, promotes angiogenesis", Circ Res, 83, pp.1059~1066 (1998)
- Izadi V, "Serum adiponectin level and different kinds of cancer: a review of recent evidence", ISRN Oncol, 2012, pp.982769~ (2012)
- Mitsiades N, "Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies", J Clin Endocrinol Metab, 96, pp.E2023~E2028 (2011)